House Amendment 717 to House Bill 3
116th Congress(2019-2020)
Amendment requires an HHS study to identify conditions without an FDA-approved treatment where the development of a treatment would fill an unmet medical need for a serious or life-threatening condition or rare disease. Also, the amendment requires HHS to identify appropriate incentives that would lead to the development of such treatments.
Agreed To
Agreed to in House on Dec 12, 2019
Origin Chamber
House
Type
Amendment
Amendment
A proposed change to a pending text (e.g., a bill, resolution, another amendment, or a treaty [or an associated resolution of ratification]).
Amendment Number
717
Congress
116
Sort by most recent
12/12/2019
House amendment agreed to: On agreeing to the Gottheimer amendment (A007) Agreed to by recorded vote: 380 - 45 (Roll no. 678).
12/12/2019
On agreeing to the Gottheimer amendment (A007) Agreed to by recorded vote: 380 - 45 (Roll no. 678).
12/12/2019
Amendment (A007) offered by Mr. Gottheimer. (consideration: CR H10210-10211, H10221; text: CR H10210)
12/12/2019
House amendment offered
Dec 12, 2019
Passed House
107
Sponsorship
Public Record
Record Updated
Feb 8, 2022 11:01:28 PM